Introduction to Current Research
Psilocybin research is experiencing a renaissance, with numerous clinical trials underway worldwide. Understanding current research helps appreciate the scientific progress, potential therapeutic applications, and the evidence base for psilocybin use. This guide provides an overview of ongoing studies, research institutions, latest findings, and the regulatory landscape.
This comprehensive guide covers current psilocybin research: ongoing clinical trials, Phase 2 and Phase 3 studies, research institutions leading the field, latest findings, FDA breakthrough therapy status, international research, and what to expect in the coming years. The research landscape is rapidly evolving, with new studies beginning regularly.
Research is expanding across multiple applications: depression, anxiety, addiction, PTSD, end-of-life anxiety, and more. Understanding current research helps contextualize the scientific evidence and potential future applications.
Ongoing Clinical Trials
Depression Studies
Multiple trials investigating psilocybin for depression:
- Treatment-resistant depression
- Major depressive disorder
- Various dosages and protocols
- Combined with therapy
- Long-term follow-up studies
Anxiety Studies
Research on anxiety applications:
- Generalized anxiety disorder
- End-of-life anxiety
- Social anxiety
- Various anxiety conditions
Addiction Treatment
Studies on addiction:
- Alcohol use disorder
- Tobacco addiction
- Opioid addiction
- Other substance use disorders
Other Applications
Research on other conditions:
- PTSD
- OCD
- Cluster headaches
- Eating disorders
- Other conditions
Phase 2 and Phase 3 Trials
Phase 2 Trials
Phase 2 trials focus on:
- Efficacy in larger groups
- Optimal dosing
- Safety in target populations
- Protocol refinement
Phase 3 Trials
Phase 3 trials are:
- Large-scale efficacy studies
- Required for regulatory approval
- Comparing to standard treatments
- Final stage before approval
Research Institutions
Leading Institutions
Key research institutions include:
- Johns Hopkins University: Pioneering research, depression, end-of-life
- Imperial College London: Brain imaging, depression, mechanisms
- New York University: End-of-life anxiety, depression
- University of California: Various applications
- Other universities worldwide
Research Organizations
Important organizations:
- MAPS: Multidisciplinary Association for Psychedelic Studies
- Heffter Research Institute: Supporting research
- Usona Institute: Research and development
- Other organizations
Latest Findings
Recent Breakthroughs
Recent research has shown:
- Significant antidepressant effects
- Long-lasting benefits
- Safety profile
- Mechanisms of action
- Optimal protocols
Key Publications
Important recent publications cover:
- Depression treatment efficacy
- Brain imaging studies
- Long-term outcomes
- Safety data
- Mechanistic studies
FDA Breakthrough Therapy Status
What is Breakthrough Therapy?
Breakthrough Therapy designation:
- FDA program for promising treatments
- Accelerated development process
- More frequent FDA communication
- Indicates significant potential
Psilocybin Status
Psilocybin has received:
- Breakthrough Therapy designation for depression
- Recognition of potential
- Accelerated development pathway
- Significant milestone
International Research
Global Studies
Research is happening worldwide:
- United States
- United Kingdom
- Canada
- Switzerland
- Other countries
Regulatory Differences
Regulatory environments vary:
- Some countries more permissive
- Different approval processes
- Varying legal frameworks
- International collaboration
Microdosing Research
Current Studies
Microdosing research includes:
- Placebo-controlled trials
- Cognitive effects
- Mood and well-being
- Various applications
Findings
Microdosing research findings:
- Mixed results
- Placebo effects significant
- Some positive findings
- More research needed
Future Research Directions
Emerging Areas
Future research may explore:
- New therapeutic applications
- Optimal protocols
- Mechanisms of action
- Long-term effects
- Combination therapies
How to Stay Updated
Resources
Stay updated through:
- Research institution websites
- Scientific journals
- Clinical trial databases
- Research organization updates
- Scientific conferences
Conclusion
Current psilocybin research is extensive and rapidly expanding. Multiple clinical trials are underway investigating various therapeutic applications, with promising results emerging. Research institutions worldwide are contributing to the growing evidence base.
FDA Breakthrough Therapy designation reflects the significant potential recognized by regulators. As research continues, we can expect more findings, refined protocols, and potentially regulatory approvals in the coming years.
Staying informed about current research helps understand the scientific evidence, potential applications, and the evolving landscape of psilocybin science. The research renaissance is providing important insights into the therapeutic potential of these remarkable substances.
Major Research Centres: Who Is Doing the Work
Johns Hopkins Center for Psychedelic and Consciousness Research
Founded in 2019 with a $17 million private donation, the Johns Hopkins Center for Psychedelic and Consciousness Research is the largest such centre in the United States and arguably the most influential globally. Led by Roland Griffiths (founding director) and Matthew Johnson, the centre has produced landmark studies on psilocybin for major depressive disorder, tobacco addiction, alcohol use disorder, anorexia nervosa, and end-of-life distress. Their 2020 study published in JAMA Psychiatry (Davis et al.) — a randomized controlled trial demonstrating large reductions in depressive symptoms after two psilocybin sessions — marked a pivotal moment in the field's credibility with regulators and the broader scientific community. Johns Hopkins researchers are also conducting neuroimaging studies to characterize how psilocybin's effects on brain network connectivity correspond to therapeutic outcomes.
NYU Langone Center for Psychedelic Medicine
New York University's center, based at NYU Langone Health, has been conducting psilocybin research since 2006, when Michael Bogenschutz and colleagues demonstrated significant reductions in existential anxiety and depression in cancer patients. Current research at NYU focuses heavily on alcohol use disorder — a 2022 randomized controlled trial published in JAMA Psychiatry (Bogenschutz et al.) found that two doses of psilocybin, combined with motivational enhancement therapy, produced significantly greater reductions in heavy drinking than active placebo plus therapy. The centre is also conducting studies on psilocybin for PTSD and tobacco dependence, and houses an active training program for psychedelic therapists.
Imperial College London Centre for Psychedelic Research
Founded in 2019 under the direction of Robin Carhart-Harris (now at UCSF), the Imperial College Centre for Psychedelic Research is the pre-eminent European research hub for psilocybin science. Imperial researchers produced the first randomized controlled trial directly comparing psilocybin therapy to a leading antidepressant (escitalopram/Lexapro), published in the New England Journal of Medicine in 2021. That study (Carhart-Harris et al.) found that psilocybin produced faster and somewhat larger reductions in depression scores, with additional differences in emotional processing and cognitive flexibility. The centre is also internationally recognized for its neuroimaging work, having used fMRI to characterize how psilocybin disrupts default mode network activity and promotes global brain connectivity — findings that have become foundational to the field's mechanistic understanding.
UC San Francisco Psychedelics Division
Robin Carhart-Harris moved to UCSF in 2021, where he leads a growing psychedelic research division within the Weill Institute for Neurosciences. UCSF is currently running trials on psilocybin for anorexia nervosa (the HOPE trial), fibromyalgia, and demoralization in HIV-positive long-term survivors. UCSF also houses the Translational Psychedelic Research (TrPR) Program, which bridges basic neuroscience and clinical applications.
FDA Breakthrough Therapy Designations: What They Mean
The FDA's Breakthrough Therapy designation is a formal acknowledgement that early clinical evidence suggests a drug may offer substantial improvement over existing therapies for a serious or life-threatening condition. It is not approval — it is an expedited development pathway that allows more frequent communication between the developer and the FDA, and rolling review of data as it is generated rather than after a complete application.
Psilocybin has received two Breakthrough Therapy designations:
- 2018 — Compass Pathways: Designation for COMP360 (synthetic psilocybin) in treatment-resistant depression (TRD). This was the first such designation for a psychedelic substance, and it marked psilocybin's formal entry into the mainstream regulatory pathway.
- 2019 — USONA Institute: Designation for psilocybin in major depressive disorder (MDD) more broadly, not limited to the treatment-resistant subpopulation. USONA is a non-profit organization, and this designation covers their formulation developed specifically for clinical use.
These designations do not mean that psilocybin will be approved or that approval is imminent. They indicate that the FDA considers the existing evidence sufficiently promising to warrant prioritized engagement during the development process.
Key Ongoing Trials as of 2026
COMP360 Phase 2b/3 (Compass Pathways)
Compass Pathways, a UK-based company, is running the largest psilocybin clinical trial program to date. Their COMP360 Phase 2b study, published in NEJM Evidence in 2022, enrolled 233 participants with treatment-resistant depression across 22 clinical sites in 10 countries. It found that the 25 mg dose produced statistically significant reductions in depression scores compared to the 1 mg control at three weeks, with a response rate of approximately 29% (versus 9% for 1 mg). However, a meaningful proportion of participants experienced transient serious adverse events, including suicidal ideation, in the days following sessions — a finding that underscored the importance of careful participant selection and post-session monitoring. Compass is now moving toward Phase 3 trials with a refined protocol designed to address the adverse event profile.
MAPP2 (MAPS — Psilocybin for PTSD)
The Multidisciplinary Association for Psychedelic Studies (MAPS), best known for its MDMA-assisted therapy program for PTSD, has expanded its research portfolio to include psilocybin. MAPS is currently conducting exploratory trials examining psilocybin-assisted therapy for PTSD in populations where MDMA may be contraindicated, building on their substantial experience with therapy protocols for trauma.
USONA MDD Phase 2 Trial (PSIL201)
The USONA Institute is running a Phase 2 randomized controlled trial (PSIL201) examining psilocybin in major depressive disorder, providing the scientific basis for their Breakthrough Therapy designation. As a non-profit, USONA aims to develop psilocybin as a generic drug rather than a proprietary product, with the goal of maximizing eventual access if regulatory approval is obtained.
Projected Timeline to Potential FDA Approval
The most optimistic projections within the research community have pointed to potential FDA submission by Compass Pathways in the late 2020s, with review and a potential approval decision in the early 2030s. These timelines are subject to significant uncertainty — Phase 3 trials are expensive, complex, and frequently encounter unexpected results that require protocol modifications or additional studies.
Even with approval, the approved formulation would be indicated only for specific conditions (most likely treatment-resistant depression initially) and would be administered only within regulated clinical settings by trained therapists. Approval would not change the legal status of psilocybin mushrooms for non-clinical use — that is determined by scheduling decisions separate from FDA drug approval.
Australia became the first country to authorize the therapeutic use of psilocybin by authorized psychiatrists in 2023, representing a different regulatory model that several other jurisdictions are monitoring closely.
Disclaimer: Research findings change rapidly. For the most current trial status, consult clinicaltrials.gov and the websites of the research institutions cited above. This page reflects information available as of mid-2026 and will become outdated as new results are published.